Business UpdateApr 27, 2026, 08:02 AM
BIVI to Host KOL Event on Bezisterim for Parkinson's Disease
AI Summary
BioVie Inc. announced it will host a virtual Key Opinion Leader (KOL) event on May 7, 2026, to discuss how bezisterim's mechanism of action could address neurodegenerative diseases, including Parkinson's. The event will feature Dr. Suzanne de la Monte and company management, providing an update on the Phase 2 trial of bezisterim (NE3107) for Parkinson's disease. Bezisterim is an investigational oral drug also being studied in trials for Long COVID and Alzheimer's disease, with topline results for Parkinson's and Long COVID expected mid-2026.
Key Highlights
- KOL event on bezisterim for neurodegenerative diseases scheduled for May 7, 2026, at 2:00 PM ET.
- Event to provide update on BioVie's Phase 2 trial evaluating bezisterim (NE3107) for Parkinson's disease.
- Bezisterim is an investigational oral drug targeting neuroinflammation and insulin resistance.
- SUNRISE-PD trial for Parkinson's disease expects topline results mid-2026.
- ADDRESS-LC trial for Long COVID is enrolling approximately 200 patients, with data expected mid-2026.
- Preliminary data from Phase 2 and Phase 3 Alzheimer's trials suggest cognitive improvements.
Price Impact
More from BIVI